Your AI-Trained Oncology Knowledge Connection!
Insight regarding the utilization of antibody-drug conjugate therapy to treat relapsed/refractory advanced bladder cancer.
EP. 1: Advanced Bladder Cancer: Adopting Newer Therapies into Clinical Practice
Bradley McGregor, MD, reacts to treatment advances for advanced bladder cancer and shares perspective on utilizing newer, novel therapies as the field continues to evolve
EP. 2: Encouraging Developments in Therapies for Relapsed/Refractory Advanced Bladder Cancer
Dr Benjamin Miron highlights data specific to treating patients with relapsed metastatic disease.
EP. 3: Treating R/R Advanced Bladder Cancer With Novel Sequencing Strategies
UCSF Health’s Vadim S. Koshkin, MD, highlights approaches for sequencing novel therapies into treatment algorithms for patients with relapsed/refractory advanced bladder cancer.
EP. 4: Study EV-103 in Advanced Bladder Cancer
Ali R. Khaki, MD, describes the impact of the EV-103 study of enfortumab vedotin in advanced bladder cancer.
EP. 5: Optimizing Therapy for Patients with Advanced Bladder Cancer
Ali R. Khaki, MD, comments on how to treat patients with advanced bladder cancer based on data demonstrated by the EV-103 study of enfortumab vedotin.
Pirtobrutinib Improves Patient-Reported Outcomes in Relapsed/Refractory CLL/SLL
MAIC Analysis Shows PFS Favorability With Zanubrutinib vs Acalabrutinib/Venetoclax in CLL
Isa-KRd Yields Prolonged MRD Negativity vs KRd in Newly Diagnosed Myeloma
Elranatamab Triplet Yields Nearly 100% ORR in Newly Diagnosed Multiple Myeloma